Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503402 | 0.89 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL10349980 | 0.89 | ALDH1A1 (0.58) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2268248 | 0.86 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL13543131 | 0.86 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL22468533 | 0.86 | MEN1 (0.66) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4442846 | 0.85 | KMT2A (0.60) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL13545125 | 0.84 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL8427919 | 0.84 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL20382395 | 0.83 | KMT2A (0.62) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3277964 | 0.83 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | claimed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | claimed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| US-4931591-A | Novel 5-amino-4-hydroxyvaleryl derivatives | CIBA-GEIGY CORPORATION (US) | 1990-06-05 | — | — | US | disclosed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | MEN1 2134/4885KMT2A 3442/4885SMN1; SMN2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.